Detail akcie Pharming Group online

Business Summary: Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Pharming Group NV revenues increased 21% to $297.2M. Net loss increased 12% to $11.8M. Revenues reflect Joenja segment increase from $18.2M to $45M, RUCONEST segment increase of 11% to $252.2M. Higher net loss reflects Proceeds from PRV sale decrease from $21.3M (income) to $0K, Research and development - Other increase of 29% to $51.6M (expense).